Kura Oncology KURA Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's amortization expense related to capitalized debt issuance costs?
- Kura Oncology (KURA) reported amortization expense related to capitalized debt issuance costs of $106K in Q1 2026.
- How has Kura Oncology's amortization expense related to capitalized debt issuance costs changed year-over-year?
- Kura Oncology's amortization expense related to capitalized debt issuance costs decreased by 20.3% year-over-year, from $133K to $106K.
- What is the long-term trend for Kura Oncology's amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), Kura Oncology's amortization expense related to capitalized debt issuance costs has grown at a 6.6% compound annual growth rate (CAGR), from $399K to $515K.